BMIQ1
MCID: BDY007
MIFTS: 43

Body Mass Index Quantitative Trait Locus 1 (BMIQ1)

Categories: Bone diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 1

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 1:

Name: Body Mass Index Quantitative Trait Locus 1 57 13
Body Mass Index 57 17
Bmi 57 48
Body Mass Index; Bmi 57
Bmiq1 57

Classifications:



External Ids:

OMIM 57 606641

Summaries for Body Mass Index Quantitative Trait Locus 1

OMIM : 57 Body mass index (BMI), which reflects the amount of fat, lean mass, and body build, is a heterogeneous trait influenced by both genetic and environmental factors. Several studies have estimated the heritability of body mass index to be 40 to 55% (Bouchard et al., 1998; Rice et al., 1999). For discussion of genetic heterogeneity of BMI quantitative trait loci and their known or possible associations with variation in specific genes, see MAPPING and MOLECULAR GENETICS sections. (606641)

MalaCards based summary : Body Mass Index Quantitative Trait Locus 1, also known as body mass index, is related to body mass index quantitative trait locus 3 and body mass index quantitative trait locus 2. An important gene associated with Body Mass Index Quantitative Trait Locus 1 is BMIQ1 (Body Mass Index QTL 1). The drugs Mecasermin and Acarbose have been mentioned in the context of this disorder. Affiliated tissues include heart, breast and liver.

Related Diseases for Body Mass Index Quantitative Trait Locus 1

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1093)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 3 12.7
2 body mass index quantitative trait locus 2 12.7
3 body mass index quantitative trait locus 5 12.7
4 body mass index quantitative trait locus 6 12.7
5 body mass index quantitative trait locus 13 12.7
6 body mass index quantitative trait locus 15 12.7
7 esophageal cancer 11.8
8 chromosome 16p11.2 deletion syndrome, 220-kb 11.5
9 hypercholesterolemia, familial, 3 11.3
10 mental retardation, x-linked 12 11.2
11 morbid obesity and spermatogenic failure 11.2
12 fatty liver disease 10.7
13 chronic kidney disease 10.7
14 liver disease 10.7
15 kidney disease 10.7
16 arteries, anomalies of 10.7
17 hyperlipoproteinemia, type iii 10.7
18 coronary artery anomaly 10.7
19 pulmonary disease, chronic obstructive 10.6
20 non-alcoholic fatty liver disease 10.6
21 end stage renal failure 10.6
22 hypercholesterolemia, familial, 1 10.6
23 rectum cancer 10.6
24 eclampsia 10.6
25 renal cell carcinoma, nonpapillary 10.6
26 pustulosis of palm and sole 10.6
27 psoriasis 10.6
28 atrial fibrillation 10.6
29 pancreatic cancer 10.5
30 congestive heart failure 10.5
31 diabetes mellitus 10.5
32 vascular disease 10.5
33 back pain 10.5
34 acute myocardial infarction 10.5
35 asthma 10.5
36 cerebrovascular disease 10.5
37 ige responsiveness, atopic 10.5
38 ischemia 10.5
39 adenocarcinoma 10.5
40 lung cancer 10.5
41 hypothyroidism 10.5
42 hyperandrogenism 10.5
43 prostate cancer 10.4
44 fatty liver disease, nonalcoholic 1 10.4
45 thyroid carcinoma 10.4
46 alzheimer disease 10.4
47 peripheral vascular disease 10.4
48 hyperuricemia 10.4
49 rhinitis 10.4
50 pulmonary embolism 10.4

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 1:



Diseases related to Body Mass Index Quantitative Trait Locus 1

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 1

Clinical features from OMIM:

606641

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 1

Drugs for Body Mass Index Quantitative Trait Locus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1069)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mecasermin Approved, Investigational Phase 4 68562-41-4
2
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
3
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
4
Linagliptin Approved Phase 4 668270-12-0 10096344
5
Succinylcholine Approved Phase 4 306-40-1 5314
6
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
7
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
8
Nifedipine Approved Phase 4 21829-25-4 4485
9
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
10
Atenolol Approved Phase 4 29122-68-7 2249
11
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
12
Norepinephrine Approved Phase 4 51-41-2 439260
13
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
14
Sertraline Approved Phase 4 79617-96-2 68617
15
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
17
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
18
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
19
Lorazepam Approved Phase 4 846-49-1 3958
20
Ziprasidone Approved Phase 4 146939-27-7 60854
21
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
22
Ethambutol Approved Phase 4 74-55-5 3279 14052
23
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
24
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
25
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
26
Desflurane Approved Phase 4 57041-67-5 42113
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
28
Vancomycin Approved Phase 4 1404-90-6 441141 14969
29
Memantine Approved, Investigational Phase 4 19982-08-2 4054
30
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
31
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
32
Racepinephrine Approved Phase 4 329-65-7 838
33
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
34
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
35
Fenofibrate Approved Phase 4 49562-28-9 3339
36
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
37
Voriconazole Approved, Investigational Phase 4 137234-62-9 71616
38
Sultamicillin Approved, Investigational Phase 4 76497-13-7
39
Sulbactam Approved Phase 4 68373-14-8
40
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
41
Drospirenone Approved Phase 4 67392-87-4 68873
42
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
43
Benzydamine Approved Phase 4 100-46-9, 642-72-8 7504
44
Potassium Citrate Approved, Investigational, Vet_approved Phase 4
45
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
46
Nadroparin Approved, Investigational Phase 4
47
Histamine Approved, Investigational Phase 4 51-45-6 774
48
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
49
Amlodipine Approved Phase 4 88150-42-9 2162
50
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639

Interventional clinical trials:

(show top 50) (show all 3627)
# Name Status NCT ID Phase Drugs
1 Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial Unknown status NCT01878994 Phase 4
2 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
3 A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With ADHD in Fed Condition Unknown status NCT02470234 Phase 4 Methylphenidate HCl ER Capsules
4 Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2) Unknown status NCT02641301 Phase 4 Sustained release morphine sulfate, 30 mg
5 The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
6 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
7 Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A 100kV Protocol Unknown status NCT00611780 Phase 4
8 The Assessment of the Effect of Vitamin D Supplementation on the Serum of AGES and Endothelialy Factors and Gene Expression of Glyoxalase Enzyme and YKL-40 Factor in PBMC Cells in the Patients With Type 2 Diabetes . Unknown status NCT03008057 Phase 4
9 Effect of Enteral Nutrition in the Outcome of Patients With Cardiovascular Surgery Unknown status NCT01432769 Phase 4
10 The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Gene Expression and Serum Levels of Some Inflammatory and Endothelial Factors in Migraine Patients Unknown status NCT02532023 Phase 4
11 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
12 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation on the Number of Oocytes Obtained During IVF in Poor Ovarian Responders Unknown status NCT02357472 Phase 4 dehydroepiandrosterone
13 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
14 Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acetate Unknown status NCT02974270 Phase 4 Leuprolide
15 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
16 Efficacy of L-arginine Treatment on Blood Pressure Control Patients With Stage 1 Hypertension Unknown status NCT02894723 Phase 4
17 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
18 A Double-blind, Randomized, Controlled, Equivalence Study Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections Unknown status NCT02612272 Phase 4 Ketorolac;Betamethasone
19 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
20 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
21 Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance, a Dehydrated Decellularized Human Amnion Membrane Allograft, Following Keloid Revision Surgery Unknown status NCT02521402 Phase 4
22 Mechanisms of Low Protein Diet Supplemented With α-ketoacids on Autophagy and Improving Muscle Wasting in Chronic Kidney Disease: the Role of Autophagy in Muscle Wasting Unknown status NCT02568020 Phase 4 keto-amino acids
23 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy and Bladder Substitutions: A Randomized Controlled Trial Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
24 Comparing Body Composition Measurements - Bioelectrical Impedance Analysis and Dual-energy X-ray Absorptiometry - in Chronic Heart Failure Unknown status NCT02686866 Phase 4
25 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
26 Effects on Glycemic Variability and Glyco-metabolic Control of Metformin, Pioglitazone and Sitagliptin in Type 2 Diabetic Patients Unknown status NCT01895569 Phase 4 Metformin;Pioglitazone;Sitagliptin
27 Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia Telangiectasia Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
28 Randomised Study to Compare the Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section.Kasr El Ainy,Egypt Experience Unknown status NCT02504749 Phase 4
29 Advancing Personalized Antidepressant Treatment Using PET/MRI Unknown status NCT02623205 Phase 4 Escitalopram;Placebo
30 Effect of Controlled Hypotension on Cerebral Oxygen Saturation in Patients Undergoing Functional Endoscopic Sinus Surgery: a Prospective Randomized Single Blind Clinical Trial Unknown status NCT02967029 Phase 4 Esmolol Hydrochloride;Remifentanil Hydrochloride
31 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
32 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
33 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
34 Transforaminal Epidural Steroid Injection in Conjunction With Pulsed Radiofrequency Treatment of the Lumbar Dorsal Root Ganglion for the Management of Chronic Lumbosacral Radicular Pain: a Randomized, Double-blind Trial Unknown status NCT02930057 Phase 4 Celestone;Control
35 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
36 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
37 Double-Blind, Multicenter, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of Creon 25000 Minimicrospheres on Body Mass Index (BMI) in Patients After Gastrectomy Completed NCT00160186 Phase 4 Pancreatin;Placebo
38 The Relationship Between Baseline Body Weight and Glycemic Control Following Metformin Extended-Release Tablets (Glucophage XR) Monotherapy in Chinese Patients With Newly Diagnosed Type 2 Diabetes Completed NCT00778622 Phase 4 Metformin XR
39 Improving Contraceptive Effectiveness in Obese Women Completed NCT01170390 Phase 4 All participants (Aviane);Portia;Aviane
40 Reduction of Adolescent Risk Factors for Type 2 Diabetes and Cardiovascular Disease Completed NCT00934570 Phase 4 Metformin and standard exercise;Metformin Intensive exercise
41 NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens Completed NCT02758522 Phase 4 Once-daily Insulin;Twice-daily Insulin;Triple-daily Insulin
42 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
43 A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin (Levemir DIET) Completed NCT01232491 Phase 4 Insulin detemir
44 Bioavailability Study of Omeprazole (20 mg) at Steady State (Multiple Dose) in Patients Who Have Undergone Bariatric Surgery Completed NCT03378960 Phase 4 Omeprazole 20mg
45 Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome Completed NCT00471523 Phase 4 Clomiphene citrate;Metformin
46 Evaluation the Effect of the Double Maintenance Dose of Clopidogrel Versus Single Dose in Patients With Coronary Artery Disease With a BMI ≥ 27 kg.m-2 Completed NCT01509365 Phase 4 clopidogrel;clopidogrel
47 Beijing Chao-Yang Hospital, Capital Medical University Completed NCT03297879 Phase 4 Exenatide or metformin hydrochloride
48 Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients With Schizophrenia or Schizoaffective Disorder Completed NCT01198353 Phase 4 Ziprasidone
49 Bioenergetic Alterations After Exenatide Administration Completed NCT00623545 Phase 4 Exenatide
50 Antibiotic Prophylaxis in Bariatric Surgery With Continuous Infusion of Cefazolin: Determination of Concentration in Adipose Tissue Completed NCT01845363 Phase 4 Cefazolin used in antimicrobial prophylaxis

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 1

Genetic Tests for Body Mass Index Quantitative Trait Locus 1

Anatomical Context for Body Mass Index Quantitative Trait Locus 1

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 1:

41
Heart, Breast, Liver, Bone, Ovary, Kidney, Testes

Publications for Body Mass Index Quantitative Trait Locus 1

Articles related to Body Mass Index Quantitative Trait Locus 1:

(show top 50) (show all 30006)
# Title Authors PMID Year
1
Genetic studies of body mass index yield new insights for obesity biology. 38 8
25673413 2015
2
New genetic loci link adipose and insulin biology to body fat distribution. 38 8
25673412 2015
3
Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. 38 8
21706003 2011
4
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. 38 8
20935630 2010
5
Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. 38 8
14569127 2003
6
A study of linkage and association of body mass index in the Old Order Amish. 38 8
12888987 2003
7
Genomewide linkage analysis of body mass index across 28 years of the Framingham Heart Study. 38 8
12355400 2002
8
Quantitative-trait loci influencing body-mass index reside on chromosomes 7 and 13: the National Heart, Lung, and Blood Institute Family Heart Study. 38 8
11713718 2002
9
Familial aggregation of body mass index and subcutaneous fat measures in the longitudinal Québec family study. 38 8
10096693 1999
10
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. 38 8
9806549 1998
11
An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. 38 8
9758619 1998
12
The genetic contribution to non-syndromic human obesity. 8
19506576 2009
13
Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. 8
19151714 2009
14
Association of single-nucleotide polymorphisms in MTMR9 gene with obesity. 8
17855449 2007
15
Genetic pleiotropy between asthma and obesity in a community-based sample of twins. 8
16337451 2005
16
Genome-wide scan of obesity in the Old Order Amish. 8
11238509 2001
17
Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. 8
10523018 1999
18
Risk factors for periprosthetic joint infection of the hip and knee. 38
31432657 2020
19
Leptin gene polymorphisms are associated with weight gain during lithium augmentation in patients with major depression. 38
30554862 2019
20
Weight among children born 2005-2011 in Nuuk at the time of school entry. 38
31116095 2019
21
The effect of prepregnancy body mass index on birth weight, preterm birth, cesarean section, and preeclampsia in pregnant women. 38
29768986 2019
22
Effects of exercise training on cardiovascular risk factors in kidney transplant recipients: a systematic review and meta-analysis. 38
31106657 2019
23
Higher body mass index is not a protective risk factor for 28-days mortality in critically ill patients with acute kidney injury undergoing continuous renal replacement therapy. 38
31424314 2019
24
Modelling the dynamics of children's gross motor coordination. 38
31170881 2019
25
Association of the body mass index with outcomes in elderly patients (≥80 years) undergoing percutaneous coronary intervention. 38
31256990 2019
26
Caloric midpoint is associated with total calorie and macronutrient intake and body mass index in undergraduate students. 38
31409139 2019
27
Effects of Body Mass Index and Biochemical Lipid Levels on Reproductive Outcomes during An Intracytoplasmic Sperm Injection: A Retrospective Study. 38
31310072 2019
28
Shared genetic influences on adolescent body mass index and brain structure: A voxel-based morphometry study in twins. 38
31163268 2019
29
Impact of body mass index on acute outcome in percutaneous coronary intervention of chronic total occlusion. 38
31360048 2019
30
McDonald versus Shirodkar cervical cerclage for the prevention of preterm birth: impact of body mass index. 38
29712493 2019
31
Thyroid hormones, metabolic syndrome and Vitamin D in middle-aged and older euthyroid subjects: a preliminary study. 38
30406357 2019
32
Bariatric surgery is independently associated with a decrease in the development of colorectal lesions. 38
31097317 2019
33
Prevalence of obstructive sleep apnea in suicidal patients with major depressive disorder. 38
31238203 2019
34
Associations between interoceptive sensitivity, intuitive eating, and body mass index in patients with anorexia nervosa and normal-weight controls. 38
30968474 2019
35
Associations of multidimensional socioeconomic and built environment factors with body mass index trajectories among youth in geographically heterogeneous communities. 38
31360629 2019
36
Association between physical multimorbidity, body mass index and mental health/disorders in a representative sample of people with obesity. 38
31201257 2019
37
Impact of genetic subtypes of Prader-Willi syndrome with growth hormone therapy on intelligence and body mass index. 38
31313492 2019
38
Association of Muscle Mass with Survival after Radical Prostatectomy in Patients with Prostate Cancer. 38
30916628 2019
39
Trajectories of body mass index, from adolescence to older adulthood, and pancreatic cancer risk; a population-based case-control study in Ontario, Canada. 38
31230151 2019
40
The effect of body mass index on the risk of surgical site infection. 38
31232239 2019
41
Impact of body mass index on post-thyroidectomy morbidity. 38
31002213 2019
42
Effect of a group medical clinic for veterans with diabetes on body mass index. 38
29338320 2019
43
Evaluating haemodialysis patient's nutritional status: Body mass index or body cell mass index? 38
30414231 2019
44
PTSD is associated with poor health behavior and greater Body Mass Index through depression, increasing cardiovascular disease and diabetes risk among U.S. veterans. 38
31338278 2019
45
A gender-stratified, multilevel latent class assessment of chronic disease risk behaviours' association with Body Mass Index among youth in the COMPASS study. 38
31254539 2019
46
Body mass index and risk of inflammatory bowel disease: A systematic review and dose-response meta-analysis of cohort studies of over a million participants. 38
31190427 2019
47
Reconsidering the relationship between fast-food outlets, area-level deprivation, diet quality and body mass index: an exploratory structural equation modelling approach. 38
31171581 2019
48
Smoking as risk factor for carpal tunnel syndrome: A birth cohort study. 38
31271456 2019
49
Body mass index in patients with Multiple Sclerosis: a meta-analysis. 38
31146649 2019
50
Overweight and obesity during adolescence increases the risk of renal cell carcinoma. 38
30790271 2019

Variations for Body Mass Index Quantitative Trait Locus 1

Copy number variations for Body Mass Index Quantitative Trait Locus 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 36096 1 71641212 72520993 Deletion NEGR1 body mass index

Expression for Body Mass Index Quantitative Trait Locus 1

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 1.

Pathways for Body Mass Index Quantitative Trait Locus 1

GO Terms for Body Mass Index Quantitative Trait Locus 1

Sources for Body Mass Index Quantitative Trait Locus 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....